Evidence map›Paper›PMID 33037240›Full record

ArticleScientific reports2020

Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.

P Pawlikowska, T Tayoun, M Oulhen, V Faugeroux, V Rouffiac, A Aberlenc, A L Pommier, A Honore, V Marty, O Bawa and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Optical and Photoacoustic Imaging.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  9. Article
  10. The avian embryo as a time-honoured animal model in developmental, biomedical and agricultural research.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. RSC medicinal chemistry · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

P PawlikowskaU981 "Identification of Molecular Predictors and New Targets for Cancer Treatment", INSERM, 94805, Villejuif, France.
T TayounU981 "Identification of Molecular Predictors and New Targets for Cancer Treatment", INSERM, 94805, Villejuif, France.
M Oulhen"Circulating Tumor Cells" Translational Platform, UMS AMMICa CNRS 3655-INSERM US23, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
V FaugerouxU981 "Identification of Molecular Predictors and New Targets for Cancer Treatment", INSERM, 94805, Villejuif, France.
V RouffiacFlow Cytometry and Imaging Platform, UMS AMMICa CNRS 3655-INSERM US23, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
A Aberlenc"Circulating Tumor Cells" Translational Platform, UMS AMMICa CNRS 3655-INSERM US23, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
A L Pommier"Circulating Tumor Cells" Translational Platform, UMS AMMICa CNRS 3655-INSERM US23, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
A HonoreGenomic Platform, CNRS UMS3655 - INSERM US23 AMMICA, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
V MartyExperimental and Translational Pathology Platform, CNRS UMS3655 - INSERM US23 AMMICA, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
O BawaExperimental and Translational Pathology Platform, CNRS UMS3655 - INSERM US23 AMMICA, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
L LacroixGenomic Platform, CNRS UMS3655 - INSERM US23 AMMICA, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
J Y ScoazecExperimental and Translational Pathology Platform, CNRS UMS3655 - INSERM US23 AMMICA, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
A ChauchereauU981 "Identification of Molecular Predictors and New Targets for Cancer Treatment", INSERM, 94805, Villejuif, France.
C Laplace-BuilheFlow Cytometry and Imaging Platform, UMS AMMICa CNRS 3655-INSERM US23, Gustave Roussy, Université Paris-Saclay, 94805, Villejuif, France.
F FaraceU981 "Identification of Molecular Predictors and New Targets for Cancer Treatment", INSERM, 94805, Villejuif, France. francoise.farace@gustaveroussy.fr.
Prédicteurs moléculaires et nouvelles cibles en oncologieInstitut Gustave Roussy · FRCentre National de la Recherche Scientifique · FRImagerie Médicale et Radiothérapie Drôme Ardèche · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The establishment of clinically relevant models for tumor metastasis and drug testing is a major challenge in cancer research. Here we report a physiologically relevant assay enabling quantitative analysis of metastatic capacity of tumor cells following implantation into the chorioallantoic membrane (CAM). Engraftment of as few as 10

Indexed as

Chorioallantoic MembraneAnimalsAntineoplastic AgentsBenzamidesCarcinoma, Non-Small-Cell LungChick EmbryoCisplatinCrizotinibDocetaxelDrug Screening Assays, AntitumorGefitinibMaleNeoplasm MetastasisNeoplastic Cells, CirculatingNitrilesPhenylthiohydantoinAntineoplastic AgentsBenzamidesCisplatinCrizotinibDocetaxelenzalutamideGefitinibNitrilesPhenylthiohydantoin

Identifiers

PMID33037240
PMCPMC7547099
OpenAlexW3091992458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.